The First Affiliated Hospital of Soochow University: Leukemia, Myeloid, Acute trials

The registry lists 49 Leukemia, Myeloid, Acute studies with The First Affiliated Hospital of Soochow University as lead sponsor. 28 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 5Phase 2 27Phase 3 15Phase 4 1No phase 11(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of VABu Conditioning Regimen in Allo-HSCT for AML PatientsNot yet recruitingNCT07762508Not applicable
• VA Consolidation in Intermediate-Risk AMLRecruitingNCT07672262Phase 2
• Venetoclax TDM in Newly Diagnosed AML: Exposure-Response and PrognosisRecruitingNCT07670130
• VABu Conditioning in Elderly AML HSCTRecruitingNCT07583888Phase 2/3
• SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDSNot yet recruitingNCT07575412Phase 2
• SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDSNot yet recruitingNCT07562568Phase 2
• A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly PatientsRecruitingNCT07500753Not applicable
• Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AMLNot yet recruitingNCT07486479Phase 3
• MRD-guided Maintenance Post-HCT: Gilteritini vs SorafenibRecruitingNCT07463651Phase 3
• Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AMLRecruitingNCT07451912Phase 1/2
• Venetoclax Combined With Azacitidine for Consolidation Therapy in AMLRecruitingNCT07425782Phase 2
• A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid LeukemiaRecruitingNCT07028073Phase 1/2
• a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid LeukemiaRecruitingNCT07007949Phase 2
• A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AMLRecruitingNCT06879847Not applicable
• Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid LeukemiaNot yet recruitingNCT06841952Not applicable
• Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute LeukemiaRecruitingNCT06816134Phase 2
• Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute LeukemiaNot yet recruitingNCT06559644Early Phase 1
• Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid LeukemiaRecruitingNCT06532552Phase 2
• Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML PatientsRecruitingNCT06394011Phase 2
• VAC Regimen for AML Patients Who Failed to Response to VA RegimenRecruitingNCT06220162Phase 2
• VA vs DA for Newly Diagnosed Hig-risk AMLRecruitingNCT05939180Phase 2/3
• Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCTRecruitingNCT05823714Phase 2
• Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AMLRecruitingNCT05805098Phase 2/3
• PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCTRecruitingNCT05772273Not applicable
• CAV Regimen for R/R AMLRecruitingNCT05657639Phase 2
• Observational Study for the Evaluation of Incidence of Systemic Mastocytosis in t(8;21) Acute Myeloid LeukemiaRecruitingNCT05504408
• AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First RemissionRecruitingNCT05404906Phase 2/3
• Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT05023707Phase 1/2
• Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AMLActive, not recruitingNCT06429098Phase 2
• Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) PatientsActive, not recruitingNCT06379360Phase 2
• Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AMLCompletedNCT05654194Phase 3
• Clinical Efficacy and Safety of CD47 Monoclonal Antibody Combined With Azacitidine in the Treatment of Recurrent AML After TransplantationStatus unknownNCT05266274Not applicable
• Investigation of the Gut Microbiota in Acute Myeloid Leukemia Receiving Two Different Induction TherapiesStatus unknownNCT05123352
• New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingNCT05029141Phase 2
• Application of Nanopore Sequencing in Newly Diagnosed Acute Myeloid Leukemia Patients With Bloodstream InfectionStatus unknownNCT05016752
• Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML)Status unknownNCT04884984Phase 1/2
• Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk FeaturesStatus unknownNCT04752527Phase 2
• PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AMLStatus unknownNCT04722952Phase 3
• CD38-targeted Chimeric Antigen Receptor T Cell (CART) in Relapesd or Refractory Acute Myeloid LeukemiaStatus unknownNCT04351022Phase 1/2
• Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML PatientsStatus unknownNCT04087967Phase 3
• Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60Status unknownNCT04083911Phase 3
• CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT03985007Phase 2
• Haplo HCT vs Haplo-cord HCT for Patients With AMLCompletedNCT03719534Phase 3
• Prognostic Values of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia Patients With Allo-HSCTStatus unknownNCT03715621
• Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCTStatus unknownNCT03256071Phase 2/3
• Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT02323022Phase 3
• Haplo-SCT vs ASCT With or Without Decitabine in AML CR1Status unknownNCT02059720Phase 3
• Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeStatus unknownNCT01809392Phase 2/3
• Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell TransplantationStatus unknownNCT01806116Phase 4